Lucira Health

First Investment: 2014

EXIT - Nasdaq: LHDXQ

Lucira developed an at-home nucleic acid amplification test for the SARS-Cov2 virus that causes Covid-19, as well as a combined Covid-flu test. Pfizer acquired Lucira’s assets in 2023.

News & Insights

News

Evolv Technology, the Leader in AI Touchless Security Screening, to Become Publicly Traded Company

By Alan Cohen

News

Rocket Lab to Become Publicly Traded Commercial Orbital Launch Company

By Matthew Ocko, Dr. Chris Boshuizen

Explore Companies

Samsara Eco

Sparing the climate through infinite recycling of plastic waste

Nium

Making green ammonia for fertilizer and energy transport

Visolis

Using synthetic biology to manufacture carbon-negative materials

Nobell Foods

Plant-grown dairy cheese